Adenosine deaminase inhibition prevents Clostridium difficile toxin A-induced enteritis in mice

Infect Immun. 2011 Feb;79(2):653-62. doi: 10.1128/IAI.01159-10. Epub 2010 Nov 29.

Abstract

Toxin A (TxA) is able to induce most of the classical features of Clostridium difficile-associated disease in animal models. The objective of this study was to determine the effect of an inhibitor of adenosine deaminase, EHNA [erythro-9-(2-hydroxy-3-nonyl)-adenine], on TxA-induced enteritis in C57BL6 mice and on the gene expression of adenosine receptors. EHNA (90 μmol/kg) or phosphate-buffered saline (PBS) was injected intraperitoneally (i.p.) 30 min prior to TxA (50 μg) or PBS injection into the ileal loop. A(2A) adenosine receptor agonist (ATL313; 5 nM) was injected in the ileal loop immediately before TxA (50 μg) in mice pretreated with EHNA. The animals were euthanized 3 h later. The changes in the tissue were assessed by the evaluation of ileal loop weight/length and secretion volume/length ratios, histological analysis, myeloperoxidase assay (MPO), the local expression of inducible nitric oxide synthase (NOS2), pentraxin 3 (PTX3), NF-κB, tumor necrosis factor alpha (TNF-α), and interleukin-1β (IL-1β) by immunohistochemistry and/or quantitative reverse transcription-PCR (qRT-PCR). The gene expression profiles of A₁, A(2A), A(2B), and A₃ adenosine receptors also were evaluated by qRT-PCR. Adenosine deaminase inhibition, by EHNA, reduced tissue injury, neutrophil infiltration, and the levels of proinflammatory cytokines (TNF-α and IL-1β) as well as the expression of NOS2, NF-κB, and PTX3 in the ileum of mice injected with TxA. ATL313 had no additional effect on EHNA action. TxA increased the gene expression of A₁ and A(2A) adenosine receptors. Our findings show that the inhibition of adenosine deaminase by EHNA can prevent Clostridium difficile TxA-induced damage and inflammation possibly through the A(2A) adenosine receptor, suggesting that the modulation of adenosine/adenosine deaminase represents an important tool in the management of C. difficile-induced disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / analogs & derivatives*
  • Adenine / pharmacology
  • Adenosine Deaminase / metabolism*
  • Adenosine Deaminase Inhibitors / pharmacology*
  • Animals
  • Bacterial Toxins / administration & dosage
  • Bacterial Toxins / toxicity*
  • Benzyl Compounds / pharmacology*
  • C-Reactive Protein / genetics
  • C-Reactive Protein / metabolism
  • Clostridioides difficile / drug effects
  • Cytokines / genetics
  • Cytokines / metabolism
  • Dose-Response Relationship, Drug
  • Enteritis / chemically induced
  • Enteritis / prevention & control*
  • Enterocolitis, Pseudomembranous / prevention & control
  • Enterotoxins / administration & dosage
  • Enterotoxins / toxicity*
  • Gene Expression Regulation / drug effects
  • Ileum / drug effects
  • Ileum / pathology
  • Mice
  • NF-kappa B / genetics
  • NF-kappa B / metabolism
  • Nerve Tissue Proteins / genetics
  • Nerve Tissue Proteins / metabolism
  • Nitric Oxide Synthase Type II / genetics
  • Nitric Oxide Synthase Type II / metabolism

Substances

  • Adenosine Deaminase Inhibitors
  • Bacterial Toxins
  • Benzyl Compounds
  • Cytokines
  • Enterotoxins
  • NF-kappa B
  • Nerve Tissue Proteins
  • erythro-(3-nonyl-p-aminobenzyl-adenine)
  • neuronal pentraxin
  • tcdA protein, Clostridium difficile
  • C-Reactive Protein
  • Nitric Oxide Synthase Type II
  • Nos2 protein, mouse
  • Adenosine Deaminase
  • Adenine